The content on this site is intended for healthcare professionals only
Dr Valentin Goede presented promising outcomes for elderly CLL patients at the 18th Congress of the European Hematology Association in Stockholm.
It has been an unresolved question whether (i) combination treatment with the chemotherapeutic drug chlorambucil plus a monoclonal CD20 antibody improves outcomes for such patients compared to treatment with chlorambucil alone and (ii) these patients benefit from the use of the novel CD20 antibody obinutuzumab (GA101) relative to the approved CD20 antibody rituximab.
The CLL11 trial conducted by the German CLL Study Group (GCLLSG) in collaboration with Hoffmann-La Roche for the first time compares directly the following treatments in elderly patients with comorbidities: GA101 plus chlorambucil, rituximab plus chlorambucil, and chlorambucil alone.
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing 1st line TKI Wisely in patients with CML
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Relapsed refractory multiple myeloma
Multiple myeloma (A cancer arising from plasma cells)
